ERBB2 and neoplasm: Most recently, the DESTINY-PanTumor02 and DESTINY-CRC02 phase II trials led to the first tumor agnostic approval of a HER2-directed therapy by the FDA in HER2-positive IHC 3+ tumors [54,55].